🌐 Worldwide oncology professionals network | Run by oncologists, for colleagues | All tumor types | Non-profit 🚨 We are #OncoAlert | Oncology360°
Worldwide
Joined March 2019
- Tweets127K
- Following139
- Followers42.8K
- Likes139K
Pinned Tweet
Visit Our New Website 🚨 Science Directly From People Who Presented It
👉 oncoalert360.com/events/esmo…
No noise. No ads. Just oncology, for colleagues, by colleagues.
OncoAlert is with you every day, not just at congresses. Our website brings you the science you need to stay up to date, with no fluff, no distractions and no advertising.
We are a non-profit Organization with one mandate: keeping colleagues worldwide up to date. For almost a decade, OncoAlert has been made 100% by physicians, by oncologists for oncologists. Some of the biggest names in oncology are part of this network, and they use it to bring new findings directly to you.
@cdanicas · @hoperugo · @DrChoueiri · @TiansterZhang · @matteolambe · @NiuSanford · @stolaney1 · @christine_lovly · @amerseburger · @GlopesMd · @tompowles1 · @montypal · @Icro_Meattini · @PGrivasMDPhD · @brian_rini · @CathyEngMD · @apolo_andrea · @AndreaNecchi · @DrSGraff · @BenWestphalen · @graokane · @to_be_elizabeth · @ElisaAgostinett · @nataliagandur · @UOzkerim · @DrMirallas · @DrYukselUrun · @Lucarecco · @mzugman · @HHorinouchi · @p_ciracimd · @DraMartinezLago · @DrVilmaPBarcia · @GIMedOnc · @MarioBalsaMD · @scocmem · @AmandaNizamMD · @GaiaGriguolo · @JankovicK · @Dr_Oncologista · @Erman_Akkus · @WeOncologists · @niklas_kluemper · @Markuseckstein3
OncoAlert retweeted
Many congratulations to Dr Eduard Batlle and their lab team from Barcelona @IRBBarcelona whose work in cancer stem cell in 2007 helped them to develop the upcoming possible new standard-of-care treatment in head and neck cancers, #Petosentamab , an antiEGFRxLGR5, later investigated in trials by Merus & @Genmab
@OncoAlert @brunolarvol @myESMO
#Oncology #headandneckCancer
OncoAlert retweeted
🧬 PD-L1 testing in advanced GC
🔬 SP263, 22C3 & 28-8
📊 TAP showed higher reproducibility than CPS
⚠️ PD-L1 discordance across clones/scoring systems associated with worse outcomes
💡 PD-L1 assays are not necessarily interchangeable!
🔗 doi.org/10.1007/s10120-026-0…
@OncoAlert @myESMO @GrupoTTD
OncoAlert retweeted
Wow, great news!!! Missed something during #ESMO26? @OncoAlert has you covered with the COMPLETE newsletter!!!
OUT TODAY!!
THE COMPLETE #ESMO26 NEWSLETTER 📰
Bringing together our top picks from the most important trials presented in Madrid, all in one email.
📩 Register to receive it: buff.ly/N5gYtAc
Curated by oncologists, for colleagues in cancer care, our mission is to make the latest oncology science accessible, relevant, and easy to digest.
We are OncoAlert 🚨 — For Colleagues, by Colleagues.
Best,
The OncoAlert Network
@cdanicas @hoperugo @DrChoueiri @TiansterZhang @matteolambe @NiuSanford @stolaney1 @christine_lovly @amerseburger @GlopesMd @tompowles1 @montypal @Icro_Meattini @PGrivasMDPhD @brian_rini @CathyEngMD @apolo_andrea @AndreaNecchi @DrSGraff @BenWestphalen @graokane @to_be_elizabeth @ElisaAgostinett @nataliagandur @UOzkerim @DrMirallas @DrYukselUrun @Lucarecco @mzugman @HHorinouchi @p_ciracimd @DraMartinezLago @DrVilmaPBarcia @GIMedOnc @MarioBalsaMD @scocmem @AmandaNizamMD @GaiaGriguolo @JankovicK @Dr_Oncologista @Erman_Akkus @WeOncologists @niklas_kluemper @Markuseckstein3
OncoAlert retweeted
New Perspectives: Patients receiving virtual sustained treatment had a 6-month quit rate nearly double that of patients receiving NCI quitline referrals. Patients using VST were nearly 4x more likely to report smoking cessation medication use.
acsjournals.onlinelibrary.wi…
@OncoAlert
OncoAlert retweeted
ctDNA clearance is only part of the story. 🎙️
In Episode 523, Jon Chatzkel joins the Uromigos to explore ctDNA findings from EV-304/KEYNOTE-B15, what they reveal about treatment response and recurrence risk, and why further validation is needed before they can guide treatment decisions.
Swipe for the highlights, then hear the full discussion: bit.ly/3Uo7jGT
#Uromigos #BladderCancer #ESMO26
Explore timely, on-the-ground coverage of key trials presented at ESMO 2026 with VJ Oncology 👉 vjoncology.com/event/esmo-20…
Insights from leading oncology experts, recorded live at the congress by our collaborators at VJ Oncology.
Visit the @VJOncology website to watch the latest coverage.
@MiriamMerad, @GynCancerMD, @josepereag, @niazi_Dr7, @C_Ricordel, @WainbergZev, @KalinskyKevin, @sara_lonardi1, @KoheiShitara, @ProfGLongMIA, @david_tougeron, @FilippoPietran4, @VanitaNoronha, @decroisette, @abhenilmittal, @changhoon_yoo, @DrSapnaPatel, @tompowles1, @AndreaNecchi, @lab_kok, @AriRosenbergMD, @DrNeilGross, @LorenzaRimassa, @_callimaco, @RandySweisMD, @kyosuke_seguchi
OncoAlert retweeted
📌Visit Our New Website 🚨 Science Directly From @OncoAlert People Who Presented It
👉 oncoalert360.com/events/esmo……
Visit Our New Website 🚨 Science Directly From People Who Presented It
👉 oncoalert360.com/events/esmo…
No noise. No ads. Just oncology, for colleagues, by colleagues.
OncoAlert is with you every day, not just at congresses. Our website brings you the science you need to stay up to date, with no fluff, no distractions and no advertising.
We are a non-profit Organization with one mandate: keeping colleagues worldwide up to date. For almost a decade, OncoAlert has been made 100% by physicians, by oncologists for oncologists. Some of the biggest names in oncology are part of this network, and they use it to bring new findings directly to you.
@cdanicas · @hoperugo · @DrChoueiri · @TiansterZhang · @matteolambe · @NiuSanford · @stolaney1 · @christine_lovly · @amerseburger · @GlopesMd · @tompowles1 · @montypal · @Icro_Meattini · @PGrivasMDPhD · @brian_rini · @CathyEngMD · @apolo_andrea · @AndreaNecchi · @DrSGraff · @BenWestphalen · @graokane · @to_be_elizabeth · @ElisaAgostinett · @nataliagandur · @UOzkerim · @DrMirallas · @DrYukselUrun · @Lucarecco · @mzugman · @HHorinouchi · @p_ciracimd · @DraMartinezLago · @DrVilmaPBarcia · @GIMedOnc · @MarioBalsaMD · @scocmem · @AmandaNizamMD · @GaiaGriguolo · @JankovicK · @Dr_Oncologista · @Erman_Akkus · @WeOncologists · @niklas_kluemper · @Markuseckstein3
OncoAlert retweeted
OUT TODAY!!
THE COMPLETE #ESMO26 NEWSLETTER 📰
Bringing together our top picks from the most important trials presented in Madrid, all in one email.
📩 Register to receive it: buff.ly/N5gYtAc
Curated by oncologists, for colleagues in cancer care, our mission is to make the latest oncology science accessible, relevant, and easy to digest.
We are OncoAlert 🚨 — For Colleagues, by Colleagues.
Best,
The OncoAlert Network
@cdanicas @hoperugo @DrChoueiri @TiansterZhang @matteolambe @NiuSanford @stolaney1 @christine_lovly @amerseburger @GlopesMd @tompowles1 @montypal @Icro_Meattini @PGrivasMDPhD @brian_rini @CathyEngMD @apolo_andrea @AndreaNecchi @DrSGraff @BenWestphalen @graokane @to_be_elizabeth @ElisaAgostinett @nataliagandur @UOzkerim @DrMirallas @DrYukselUrun @Lucarecco @mzugman @HHorinouchi @p_ciracimd @DraMartinezLago @DrVilmaPBarcia @GIMedOnc @MarioBalsaMD @scocmem @AmandaNizamMD @GaiaGriguolo @JankovicK @Dr_Oncologista @Erman_Akkus @WeOncologists @niklas_kluemper @Markuseckstein3
🤖 Made with AI
OncoAlert retweeted
🧬 Early-onset colorectal cancer: a distinct tumor ecosystem?
• 🌐 Stromal enrichment: Younger MSS tumors exhibit ↑ stromal/epithelial ratio, validated in 712 tumors.
• 🔀 EMT signaling: ↑ inferred FN1, GDF, ACTIVIN & SPP1 interactions suggest enhanced tumor–stroma crosstalk.
• 🧬 Transcriptional rewiring: ↑ lncRNA expression, including poorly characterized transcripts, in younger MSS tumors.
• 🔬 Genomic landscape: CNA patterns largely conserved across ages, with a trend toward greater intratumoral heterogeneity (P=0.056).
• 🎯 Therapeutic opportunities: Stromal remodeling & EMT-associated signaling emerge as potential vulnerabilities.
📄 doi.org/10.1038/s41591-026-0…
OncoAlert retweeted
GDF15 neutralization may enable boosting CR rare of EVP allowing surgical and adjuvant therapy de-escalation in MIBC deep responders.
GDFather-Neo was a successful 🇩🇪🇮🇹 trial
Clinical research in 🇪🇺 EU is at a critical step urgent changes are needed
Next week an important bladder cancer table at the EU parliament
@EU_Commission @JNJInnovMedEMEA
#Catalym
nature.com/articles/s41591-0…
OncoAlert retweeted
🔥Ph2 Peri-operative RASi (HRS-4642, G12D)+ GnP +/-adebrelimab (PD-L1)
➡️two cohorts n=60 #PDAC
➡️safety- mainly haem, none precluded surgery
➡️ORR 63% & 87%;MPR in 17%
➡️R0 resection rate 100%
✅6 mth EFS rate 87% & 96%
➡️100% ⬇️CA19.9; OS pending
@myESMO #ESMO26 @OncoAlert
OncoAlert retweeted
Excellent discussion @MarioBalsaMD. Not so long ago you were one of my students and we grew together in many ways. I am so proud of you Mario, always🥹!!!! @OncoAlert at #ESMO26
🎬 New #OAOnTheGo 🎥 from #ESMO26
Our #OncoAlertAF colleagues & Melanoma specialist Dr. @MarioBalsaMD (Hospital Clínic Barcelona) on treating patients who don’t fit the trials:
🤰 Melanoma in pregnancy: very limited data, and none at all for anti-LAG3
Transplant recipients: checkpoint inhibitors can work, but rejection occurs in ~1 in 3
Immunotherapy is never just about the tumor 👇
#ESMO26 #Melanoma
@DrBetofMDPhD @cdanicas, @matteolambe, @NiuSanford, @GlopesMd, @PGrivasMDPhD, @brian_rini, @to_be_elizabeth, @ElisaAgostinett, @nataliagandur, @UOzkerim, @DrMirallas, @DrYukselUrun, @Lucarecco, @mzugman, @HHorinouchi, @p_ciracimd, @DraMartinezLago, @DrVilmaPBarcia, @GIMedOnc, @MarioBalsaMD, @scocmem, @AmandaNizamMD, @GaiaGriguolo, @JankovicK, @Dr_Oncologista, @Erman_Akkus, @WeOncologists, @niklas_kluemper, @Markuseckstein
OncoAlert retweeted
Overall survival from phIII postMONARCH trial of abemaciclib + fulvestrant v placebo + fulv for HR+ HER2- advanced breast cancer following progression on a prior CDK4/6 inhibitor plus endocrine therapy annalsofoncology.org/article… #ESMO26 @OncoAlert @KalinskyKevin @Annals_Oncology
OncoAlert retweeted
#ESMO26 Long-term EV-103 follow-up (up to 7 years) shows remarkable durability with ~30% of responders still in response at 7 years
The next step is identifying long-term responders through biomarkers (Nectin4?) and optimising treatment duration (ctDNA?)
@OncoAlert
OncoAlert retweeted
#ESMO26 🇪🇸 Proud to present our BeTAS ePoster (906eP)! 🧬
📊 222 RAS/BRAF WT mCRC pts
💊 FTD/TPI + BEV | Real-world data
📈 mPFS 4.3 mo | mOS 10.7 mo
🎯 ORR 8.5% | DCR 51.2%
🔬 Tabernero score & G3–4 neutropenia: prognostic factors.
👏 Great collaborative work!
@OncoAlert
OncoAlert retweeted
#ESMO26 ❌ KEYNOTE-975 | Phase III
👥 700 pts | Unresectable EC/GEJ
💊 Pembro + dCRT vs placebo + dCRT
🔬 PD-L1 CPS≥10:
📉 EFS: 15.2 vs 14.7 mo (HR 0.97; p=0.399)
⏳ OS: 32.2 vs 35.0 mo (HR 1.00)
📊 Overall EFS: HR 0.94
🛑 Negative trial. No EFS benefit.
@OncoAlert
OncoAlert retweeted
#ESMO26 🇪🇸 Excited to present another BeTAS study poster tomorrow!
🧬 833P: FTD/TPI + BEV across age groups in mCRC
📊 RWE from the BeTAS study
📍 Poster Session
🕛 Sunday 25th | 12:00
👏 Proud of this great multicenter collaboration!
@OncoAlert @Grupo_GITUD @GrupoTTD @myESMO